{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:46:07Z","timestamp":1773924367948,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009248","name":"Innovatiefonds Zorgverzekeraars","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Older patients using antihypertensive medication may experience Adverse Drug Events (ADEs), and thus benefit from deprescribing. The lack of a practical protocol may hamper deprescribing. Therefore, we aimed to develop a deprescribing protocol, based on a review of literature, combined with a feasibility test in a small number of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A deprescribing protocol for general practitioners was drafted and tested in older patients using multiple antihypertensive medication in a single arm intervention. Patients were included if they were 75\u00a0years or older, were using two or more antihypertensives, had at least one ADE linked to antihypertensive medication and deprescribing was considered to be safe by their general practitioner. The primary outcome was the percentage of patients for whom one or more antihypertensive drugs were stopped or reduced in dose after 12\u00a0months of follow up while maintaining safe blood pressures. Secondary outcomes were the proportion of patients reporting no ADEs after 12\u00a0months and the number of deprescribed antihypertensives. Patient\u2019s opinions on deprescribing and enablers and barriers for study participation were also collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine general practitioners included 14 patients to deprescribe antihypertensive medication using the deprescribing protocol. After 12\u00a0months antihypertensive drug use was lowered in 11 patients (79%). These patients had a mean systolic blood pressure increase of 16\u00a0mmHg and a mean diastolic blood pressure increase of 8\u00a0mmHg. Nine patients (64%) reported experiencing no ADEs anymore after twelve months. The mean number of deprescribed antihypertensives was 1.1 in all patients and 1.4 (range: 0.5 to 3.5) in patients who successfully lowered their medication.<\/jats:p>\n                <jats:p>At baseline, being able to use less medication was the most frequently mentioned enabler to participate in this study. The most frequently mentioned positive experience at the end of the study was using less medication, which was in line with the most mentioned enabler to participate in this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A protocol for deprescribing antihypertensives in older patients was considered feasible, as it resulted in a substantial degree of safe deprescribing in this pilot study. Larger studies are needed to demonstrate the effect and safety of deprescribing antihypertensives in older patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12875-022-01894-6","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T07:02:58Z","timestamp":1667977378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Feasibility of a protocol for deprescribing antihypertensive medication in older patients in Dutch general practices"],"prefix":"10.1186","volume":"23","author":[{"given":"Dimokrat","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorie","family":"Versmissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Hek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liset","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia M. L. A.","family":"van den Bemt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"issue":"34","key":"1894_CR1","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484 (PMID: 34458905).","journal-title":"Eur Heart J."},{"issue":"18","key":"1894_CR2","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887\u201398. https:\/\/doi.org\/10.1056\/NEJMoa0801369.","journal-title":"N Engl J Med."},{"issue":"22","key":"1894_CR3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1511939.","journal-title":"N Engl J Med."},{"key":"1894_CR4","unstructured":"Nederlands Huisartsen Genootschap (NHG), 2019. Cardiovascular Risk Management (M84) [In Dutch]. NHG-guidelines. Nederlands Huisartsen Genootschap (NHG). Retrieved from: https:\/\/richtlijnen.nhg.org\/standaarden\/cardiovasculair-risicomanagement#volledige-tekst-medicamenteuze-behandeling"},{"key":"1894_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/pds.5122","volume":"29","author":"F Lghoul-OuladSa\u00efd","year":"2020","unstructured":"Lghoul-OuladSa\u00efd F, Hek K, Flinterman LE, et al. Prevalence and incidence rate of hospital admissions related to medication between 2008 and 2013 in The Netherlands. Pharmacoepidemiol Drug Saf. 2020;29:1659\u201368. https:\/\/doi.org\/10.1002\/pds.5122.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"3","key":"1894_CR6","doi-asserted-by":"publisher","first-page":"afac045","DOI":"10.1093\/ageing\/afac045","volume":"51","author":"A Hussain","year":"2022","unstructured":"Hussain A, Ali K, Parekh N, Stevenson JM, Davies JG, Bremner S, Rajkumar C, PRIME study group. Characterising older adults\u2019 risk of harm from blood-pressure lowering medications: a sub-analysis from the PRIME study. Age Ageing. 2022;51(3):afac045. https:\/\/doi.org\/10.1093\/ageing\/afac045 (PMID: 35352796; PMCID: PMC8966023).","journal-title":"Age Ageing."},{"key":"1894_CR7","doi-asserted-by":"publisher","unstructured":"Sheppard JP, Benetos A, McManus RJ. Antihypertensive Deprescribing in Older Adults: a Practical Guide. Curr Hypertens Rep. 2022. https:\/\/doi.org\/10.1007\/s11906-022-01215-3. Epub ahead of print. PMID: 35881225.","DOI":"10.1007\/s11906-022-01215-3"},{"key":"1894_CR8","doi-asserted-by":"publisher","unstructured":"Hassan D, Peeters LEJ, Koch BCP, Versmissen J. DiffErenCes in AntihypertenSive Drug Blood Levels in Patients with HypertensiON (DECISION): Protocol for a Prospective Observational Study Comparing Pharmacokinetics and Pharmacodynamics Between Young and Elderly Patients. High Blood Press Cardiovasc Prev. 2022. https:\/\/doi.org\/10.1007\/s40292-022-00505-w. Epub ahead of print. PMID: 35175576.","DOI":"10.1007\/s40292-022-00505-w"},{"issue":"4","key":"1894_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/17425255.2019.1588249","volume":"15","author":"LEJ Peeters","year":"2019","unstructured":"Peeters LEJ, Kester MP, Feyz L, Van Den Bemt PMLA, Koch BCP, Van Gelder T, Versmissen J. Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension. Expert Opin Drug Metab Toxicol. 2019;15(4):287\u201397. https:\/\/doi.org\/10.1080\/17425255.2019.1588249.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"1894_CR10","unstructured":"Geijteman, E.C.T. (2018, December 12). Decisions about medical treatment in the last phase of life : Withholding and withdrawing medication and other interventions. Erasmus University Rotterdam. Retrieved from http:\/\/hdl.handle.net\/1765\/111500"},{"issue":"6","key":"1894_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamainternmed.2014.8012","volume":"175","author":"A Benetos","year":"2015","unstructured":"Benetos A, Labat C, Rossignol P, et al. Treatment With Multiple Blood Pressure Medications, Achieved Blood Pressure, and Mortality in Older Nursing Home Residents: The PARTAGE Study. JAMA Intern Med. 2015;175(6):989\u201395. https:\/\/doi.org\/10.1001\/jamainternmed.2014.8012.","journal-title":"JAMA Intern Med."},{"key":"1894_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3389\/fphar.2020.01268","volume":"11","author":"S Crutzen","year":"2020","unstructured":"Crutzen S, Baas G, Abou J, van den Born-Bondt T, Hugtenburg JG, Bouvy ML, Heringa M, Taxis K, Denig P. Barriers and Enablers of Older Patients to Deprescribing of Cardiometabolic Medication: A Focus Group Study. Front Pharmacol. 2020;11:1268. https:\/\/doi.org\/10.3389\/fphar.2020.01268 (PMID: 32973509; PMCID: PMC7468428).","journal-title":"Front Pharmacol."},{"key":"1894_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12875-019-0953-4","volume":"20","author":"S Zechmann","year":"2019","unstructured":"Zechmann S, Trueb C, Valeri F, et al. Barriers and enablers for deprescribing among older, multimorbid patients with polypharmacy: an explorative study from Switzerland. BMC Fam Pract. 2019;20:64. https:\/\/doi.org\/10.1186\/s12875-019-0953-4.","journal-title":"BMC Fam Pract"},{"key":"1894_CR14","unstructured":"Luymes, C.H. (2018, June 07). To stop or not to stop : deprescribing preventive cardiovascular medication in low-risk general practice patients. University of Leiden. Retrieved from http:\/\/hdl.handle.net\/1887\/63081"},{"key":"1894_CR15","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1002\/hsr2.45","volume":"1","author":"RJ Gillespie","year":"2018","unstructured":"Gillespie RJ, Harrison L, Mullan J. Deprescribing medications for older adults in the primary care context: A mixed studies review. Health Sci Rep. 2018;1:e45. https:\/\/doi.org\/10.1002\/hsr2.45.","journal-title":"Health Sci Rep."},{"issue":"4","key":"1894_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1370\/afm.2094","volume":"15","author":"KA Wallis","year":"2017","unstructured":"Wallis KA, Andrews A, Henderson M. Swimming Against the Tide: Primary Care Physicians\u2019 Views on Deprescribing in Everyday Practice. Ann Fam Med. 2017;15(4):341\u20136. https:\/\/doi.org\/10.1370\/afm.2094 (PMID: 28694270; PMCID: PMC5505453).","journal-title":"Ann Fam Med."},{"issue":"4","key":"1894_CR17","doi-asserted-by":"publisher","first-page":"e0151066","DOI":"10.1371\/journal.pone.0151066","volume":"11","author":"NJ Ailabouni","year":"2016","unstructured":"Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS ONE. 2016;11(4):e0151066. https:\/\/doi.org\/10.1371\/journal.pone.0151066.","journal-title":"PLoS ONE"},{"key":"1894_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11096-021-01336-w","volume":"44","author":"B Tangiisuran","year":"2022","unstructured":"Tangiisuran B, Rajendran V, Sha\u2019aban A, et al. Physicians\u2019 perceived barriers and enablers for deprescribing among older patients at public primary care clinics: a qualitative study. Int J Clin Pharm. 2022;44:201\u201313. https:\/\/doi.org\/10.1007\/s11096-021-01336-w.","journal-title":"Int J Clin Pharm"},{"issue":"20","key":"1894_CR19","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1001\/jama.2020.4871","volume":"323","author":"JP Sheppard","year":"2020","unstructured":"Sheppard JP, Burt J, Lown M, Temple E, Lowe R, Fraser R, Allen J, Ford GA, Heneghan C, Hobbs FDR, Jowett S, Kodabuckus S, Little P, Mant J, Mollison J, Payne RA, Williams M, Yu LM, McManus RJ, OPTIMISE Investigators. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. JAMA. 2020;323(20):2039\u201351. https:\/\/doi.org\/10.1001\/jama.2020.4871.","journal-title":"JAMA."},{"issue":"9","key":"1894_CR20","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1097\/HJH.0000000000001405","volume":"35","author":"V van der Wardt","year":"2017","unstructured":"van der Wardt V, Harrison JK, Welsh T, Conroy S, Gladman J. Withdrawal of antihypertensive medication: a systematic review. J Hypertens. 2017;35(9):1742\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000001405 (PMID:28486271; PMCID:PMC5548513).","journal-title":"J Hypertens"},{"key":"1894_CR21","unstructured":"Primary Health Tasmania. (2019). A guide to deprescribing antihypertensive agents. Primary Health Tasmania (Tasmania PHN). Retrieved from https:\/\/www.primaryhealthtas.com.au\/wp-content\/uploads\/2018\/09\/A-Guide-to-Deprescribing-Antihypersensitive-Agents-2019.pdf"},{"key":"1894_CR22","unstructured":"Harrison JK, et al. Proposed antihypertensive medication withdrawal protocol. East Midlands Research into Ageing Network (EMRAN) discussion paper series. The University of Nottingham; 2016. Issue 8. ISSN: 2059-3341."},{"key":"1894_CR23","unstructured":": NHV. (2022). Measuring blood pressure [in Dutch] - Nederlandse Hypertensie Vereniging. Retrieved from https:\/\/hypertensie.nl\/bloeddruk-meten\/"},{"issue":"1","key":"1894_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12916-017-0988-0","volume":"16","author":"CH Luymes","year":"2018","unstructured":"Luymes CH, Poortvliet RKE, van Geloven N, de Waal MWM, Drewes YM, Blom JW, Smidt N, Assendelft WJJ, van den Hout WB, de Ruijter W, Numans ME. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial. BMC Med. 2018;16(1):5. https:\/\/doi.org\/10.1186\/s12916-017-0988-0 (PMID: 29321031; PMCID: PMC5763574).","journal-title":"BMC Med."},{"key":"1894_CR25","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jclinepi.2015.04.014","volume":"68","author":"W Viechtbauer","year":"2015","unstructured":"Viechtbauer W, Smits L, Kotz D, Bud\u00e9 L, Spigt M, Serroyen J, Crutzen R. A simple formula for the calculation of sample size in pilot studies. J Clin Epidem. 2015;68:1375\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.04.014.","journal-title":"J Clin Epidem"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-022-01894-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-022-01894-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-022-01894-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T07:03:11Z","timestamp":1667977391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-022-01894-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1894"],"URL":"https:\/\/doi.org\/10.1186\/s12875-022-01894-6","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"3 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Erasmus MC medical ethical review committee (MEC-2019\u20130197).An Informed Consent (IC) was obtained for all patients, wherein patients give their explicit consent for study participation.The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.No information will be spread or published that can be traced back to the subject\u2019s identity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LvD received funding from TEVA Pharmaceuticals and Biogen for studies not related to this study.All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}